Heart Rhythm Society Scientific Sessions, April 24–27, 2025 – San Diego, CA.
Heart Rhythm Society Scientific Sessions, April 24–27, 2025 – San Diego, CA.
Pulsed Field Ablation (PFA) is emerging as a highly promising technique for atrial fibrillation (AF) ablation due to its tissue-selective, non-thermal mechanism and strong safety profile. At Heart Rhythm 2025, updated data confirmed that PFA is effective in both paroxysmal and persistent AF. For paroxysmal AF, studies report 78–88% freedom from arrhythmia at 12 months, while in persistent AF, success rates range from 58% to 73%, depending on the system and approach used. For example, the ADVANTAGE-AF study of the Farapulse system showed 73.4% success at one year, well above the trial’s 40% benchmark.
Importantly, PFA shows high safety, with multiple trials reporting very low complication rates—often below 3%, and in some cases, zero serious adverse events, including no phrenic nerve injury or esophageal damage, which are common concerns with thermal ablation techniques.
PFA is also being investigated beyond AF, including in scar-related ventricular tachycardia (VT), with early data (FieldForce system) showing 78% freedom from VT post-procedure, suggesting expanding potential in complex arrhythmias.
There is currently no widely published clinical data supporting the routine use of Pulsed Field Ablation (PFA) for typical supraventricular tachycardias (SVTs) such as:
• AVNRT (atrioventricular nodal reentrant tachycardia)
• AVRT (atrioventricular reentrant tachycardia)
• Atrial tachycardia
The reason is that these types of SVT are already effectively treated with radiofrequency ablation (RF) or cryoablation, both of which are well-established, safe, and typically do not cause damage to surrounding tissues as may occur in AF ablation
Reference:
Mount Sinai Clinical Reports – Heart Rhythm 2025 Summary:
https://reports.mountsinai.org/article/card2025-_8_pulsed-field-ablation
